Regarding the sites where immune checkpoint molecules work, it is now considered that CTLA-4 acts as a negative regulator of the initial activation of T cells in regional lymph nodes, and PD-1 ligands suppress T-cell activation in the tumor microenvironment [18]. The gene discussed is CTLA4; the disease is neoplasm.